| A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ... Clinical cancer research 23 (1), 26-34, 2017 | 357 | 2017 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 348 | 2019 |
| Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer VM Jansen, NE Bhola, JA Bauer, L Formisano, KM Lee, KE Hutchinson, ... Cancer research 77 (9), 2488-2499, 2017 | 234 | 2017 |
| CDK 4/6 inhibitors as single agent in advanced solid tumors F Schettini, I De Santo, CG Rea, P De Placido, L Formisano, M Giuliano, ... Frontiers in oncology 8, 608, 2018 | 202 | 2018 |
| Mechanisms of lapatinib resistance in HER2-driven breast cancer V D’Amato, L Raimondo, L Formisano, M Giuliano, S De Placido, R Rosa, ... Cancer treatment reviews 41 (10), 877-883, 2015 | 194 | 2015 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 139 | 2017 |
| Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ... Science translational medicine 9 (402), eaai7993, 2017 | 130 | 2017 |
| Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models R Rosa, R Marciano, U Malapelle, L Formisano, L Nappi, C D'Amato, ... Clinical cancer research 19 (1), 138-147, 2013 | 123 | 2013 |
| Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer S Croessmann, L Formisano, LN Kinch, PI Gonzalez-Ericsson, ... Clinical Cancer Research 25 (1), 277-289, 2019 | 122 | 2019 |
| Role of FGFR3 in bladder cancer: Treatment landscape and future challenges CM Ascione, F Napolitano, D Esposito, A Servetto, S Belli, A Santaniello, ... Cancer Treatment Reviews 115, 102530, 2023 | 114 | 2023 |
| Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population NE Bhola, VM Jansen, JP Koch, H Li, L Formisano, JA Williams, ... Cancer research 76 (2), 440-452, 2016 | 108 | 2016 |
| The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models V D'amato, R Rosa, C D'amato, L Formisano, R Marciano, L Nappi, ... British journal of cancer 110 (12), 2887-2895, 2014 | 102 | 2014 |
| Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers C Di Mauro, R Rosa, V D'Amato, P Ciciola, A Servetto, R Marciano, ... British journal of cancer 116 (11), 1425-1435, 2017 | 98 | 2017 |
| Combining immune checkpoint inhibitors with anti-angiogenic agents P Ciciola, P Cascetta, C Bianco, L Formisano, R Bianco Journal of clinical medicine 9 (3), 675, 2020 | 91 | 2020 |
| Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors CD Mauro, A Pesapane, L Formisano, R Rosa, V D’Amato, P Ciciola, ... Scientific reports 7 (1), 9388, 2017 | 85 | 2017 |
| FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer JZ Drago, L Formisano, D Juric, A Niemierko, A Servetto, SA Wander, ... Clinical Cancer Research 25 (21), 6443-6451, 2019 | 82 | 2019 |
| Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models L Formisano, L Nappi, R Rosa, R Marciano, C D’Amato, V D’Amato, ... Breast Cancer Research 16, 1-15, 2014 | 81 | 2014 |
| c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve? S Belli, D Esposito, A Servetto, A Pesapane, L Formisano, R Bianco Cancers 12 (6), 1489, 2020 | 74 | 2020 |
| Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 N Luo, L Formisano, PI Gonzalez-Ericsson, V Sanchez, PT Dean, ... Oncoimmunology 7 (6), e1438106, 2018 | 71 | 2018 |
| Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells C D’amato, R Rosa, R Marciano, V D’amato, L Formisano, L Nappi, ... British journal of cancer 111 (6), 1168-1179, 2014 | 64 | 2014 |
